The global pulmonary function testing systems market size accounted for USD 5.3 billion in 2025 and is predicted to increase from USD 5.66 billion in 2026 to approximately USD 10.23 billion by 2035, expanding at a CAGR of 6.8% from 2026 to 2035. A substantial growth in respiratory disease prevalences, & vast demand for portable, home-based & AI-driven solutions fuel the overall market growth.
The pulmonary function testing systems market encompasses diverse, robust non-invasive diagnostic tools, like spirometers, plethysmography boxes, & gas analyzers to capture lung volume, capacity, airflow, & gas exchange. These solutions have pivotal role in categorizing lung concerns as obstructive or restrictive by recording FEV1, FVC, & TLC. Also, they have a key significance in monitoring the growth of chronic respiratory diseases & evaluating the efficacy of treatments.
Eventual developments will pose emphasis on handheld spirometers and portable systems to enable testing in physician offices, clinics, & at the bedside. Moreover, the market will increasingly shift towards home testing, enhancing disease management for chronic issues & minimizing the need for in-person hospital visits. Specifically, the wider use of machine learning will support the analysis of consistent data, like complete flow-volume loops, to offer detailed insights into small airway function.
The above estimations show the higher need for regular spirometry, which enables monitoring the long-term decline in lung function, & for further finding prognosis & the acceleration of disease progression. Besides this, these systems will foster pre-surgical risk assessment, occupational health surveillance, & determine physiological changes.
North America held the largest share of 40% of the market in 2025, due to the presence of a well-developed medical system & increased healthcare spending. Many U.S. giant firms are emphasizing integration of AI for automatic interpretation, quality control, & predictive analysis to enhance diagnostic accuracy. Impressive steps include the widespread adoption of compact, cabinless, & digital testing devices to facilitate full-body plethysmography results.
Asia Pacific held 20% share of the pulmonary function testing systems market in 2025 & is expected to register rapid growth at 7.00% CAGR in the studied years. A huge rise in urbanization & broader awareness regarding respiratory health & early diagnosis, coupled with extensive healthcare infrastructure, impels the use of PFT systems in hospitals & outpatient clinics. China is heavily fostering AI-powered quality checks for spirometry, Electrical Impedance Tomography (EIT) for imaging, & domestic production of specialized sensors.
This market has four leading firms, called MGC Diagnostics Corporation, Vyaire Medical, COSMED srl, and ndd Medical Technologies. From these companies, MGC Diagnostics is the largest shareholder & also a part of CAIRE Inc., which emphasizes emerging advanced software for interpreting data & enhancing the accuracy of gas exchange testing.
By Type
By End-User
By Application
By Region
